Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
Healthcare
$15.78 -0.39%
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
52W Low $7.91High $28.72
Volume 1.07M
Average 1.17M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$482.00M
FY 2025 · Annual
Investing Cash Flow
$66.00M
FY 2025 · Annual
Financing Cash Flow
$488.00M
FY 2025 · Annual
+76.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 52.83M | (267M) | (307M) | (283M) | (353M) |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 55M | 65M | 73M | 76M | 60M |
| Change in Working Capital | (375.62M) | 623M | (71M) | 22M | (194M) |
| Accounts Receivables | (17.05M) | 704M | 15M | 28M | 9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.77M) | 8M | (1M) | 3M | 24M |
| Other Working Capital | (353.8M) | (89M) | (85M) | (9M) | (227M) |
| Other Non-Cash Items | 7.62M | 11M | (9M) | 5M | (5M) |
| Operating Cash Flow | (256.17M) | 438M | (306M) | (170M) | (482M) |
| Capital Expenditures | (26.08M) | (6M) | (24M) | (6M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (718.87M) | (1.24B) | (788M) | (1.04B) | (1.08B) |
| Sales of Investments | 741.08M | 837M | 1.01B | 965M | 1.14B |
| Other Investing Activities | 0 | (3M) | 0 | 0 | 0 |
| Investing Cash Flow | (3.87M) | (413M) | 194M | (84M) | 66M |
| Debt Repayment | 5M | 0 | 0 | 47M | 49M |
| Common Stock Issued | 232.35M | 23M | 25M | 228M | 439M |
| Common Stock Repurchased | (6K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 10M | 8M | 2M | 0 |
| Financing Cash Flow | 237.34M | 33M | 33M | 277M | 488M |
| Effect of Forex Changes | (2.8M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | (25.5M) | 58M | (79M) | 23M | 72M |
| Free Cash Flow | (282.25M) | 432M | (330M) | (176M) | (484M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$353.0M
+ D&A$10.0M
+ Stock-Based Comp$60.0M
+ Deferred Tax$0
- Working Capital-$194.0M
- Other Non-Cash-$5.0M
= Operating Cash Flow-$482.0M
- Capex-$2.0M
= Free Cash Flow-$484.0M
Analysis
FY2025 free cash flow is -$484.0M. FCF conversion is 137.1% of net income. Operating cash flow was -$482.0M, with capex of -$2.0M. The largest bridge item is Working Capital at -$194.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 8-K | Current report | Oct 23, 2026 | |
| 424B5 | 424B5 filing | Oct 22, 2026 | |
| 8-K | Current report | Oct 21, 2026 |
Does RCUS generate free cash flow?
Arcus Biosciences, Inc. (RCUS) generated -$484.00M of free cash flow in fiscal 2025.
How much operating cash flow does RCUS produce?
Operating cash flow was -$482.00M, before capital expenditures of $2.00M.
Continue the stock analysis
Jump to another research area for this company.